Subretinal Hyperreflective Material (SHRM) as biomarker of activity in Exudative and Non- exudative inflammatory choroidal neovascularization,Ocular Immunology and Inflammation

当前位置： X-MOL 学术 › Ocul. Immunol. Inflamm. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Subretinal Hyperreflective Material (SHRM) as biomarker of activity in Exudative and Non- exudative inflammatory choroidal neovascularization
Ocular Immunology and Inflammation ( IF 3.3 ) Pub Date : 2021-10-14 , DOI: 10.1080/09273948.2021.1980813
Atul Arora ₁ , Aniruddha Agarwal ₁ , Reema Bansal ₁ , Deeksha Katoch ₁ , Alessandro Marchese ₂ , Kanika Aggarwal ₁ , Rupesh Agrawal _{3,

4,

5,

6} , Vishali Gupta ₁

Affiliation

ABSTRACT

Aim

To analyze the structural features and therapeutic response in clinical and subclinical inflammatory choroidal neovascularization (i-CNV) detected inside subretinal hyperreflective material (SHRM) using swept-source optical coherence tomography (SS-OCT) and SS-OCT angiography (SS-OCTA).

Methods

In this prospective interventional study, subjects with quiescent posterior uveitis presenting with SHRM on SS-OCT and CNV network on SS-OCTA were included. Subjects with intraretinal fluid/subretinal fluid (IRF/SRF) received intravitreal antivascular endothelial growth factor (anti-VEGF) injections, while those with no IRF/SRF either received treatment or observation for 6 months until they developed IRF/SRF or decrease in best-corrected visual acuity (BCVA)/metamorphopsia. Serial comparisons included SHRM width and height and intrinsic flow signal on OCTA.

Results

28 eyes of 22 subjects (12 males; mean age: 29.52 ± 12.56 years) were evaluated. Subjects with IRF/SRF at baseline (n = 6 eyes; termed as exudative iCNVs) receiving treatment showed significant improvement in BCVA (p = .017), SHRM width/height and flow signal (p < .05). Among eyes with no IRF/SRF (n = 22; termed as non-exudative iCNVs), 7 received treatment and showed significant improvement in SHRM parameters and BCVA (p < .05). 4/15(26.67%) eyes that received no treatment developed IRF/SRF upon 6-month follow-up.

Conclusion

SHRM may act as a useful biomarker to monitor activity and response to therapy in eyes with iCNV.

中文翻译：

视网膜下高反射材料 (SHRM) 作为渗出性和非渗出性炎性脉络膜新生血管活性的生物标志物

摘要

目的

使用扫描源光学相干断层扫描 (SS-OCT) 和 SS-OCT 血管造影 (SS-OCTA) 分析在视网膜下高反射材料 (SHRM) 内检测到的临床和亚临床炎症性脉络膜新生血管 (i-CNV) 的结构特征和治疗反应.

方法

在这项前瞻性干预研究中，包括在 SS-OCT 上显示 SHRM 和在 SS-OCTA 上显示 CNV 网络的静止性后葡萄膜炎受试者。有视网膜内积液/视网膜下积液 (IRF/SRF) 的受试者接受玻璃体内抗血管内皮生长因子 (抗 VEGF) 注射，而没有 IRF/SRF 的受试者接受治疗或观察 6 个月，直到他们出现 IRF/SRF 或最佳状态下降-矫正视力（BCVA）/视物变形。系列比较包括 SHRM 宽度和高度以及 OCTA 上的固有流量信号。

结果

对 22 名受试者（12 名男性；平均年龄：29.52 ± 12.56 岁）的 28 只眼睛进行了评估。接受治疗的基线 IRF/SRF 受试者（n = 6 只眼睛；称为渗出性 iCNV）显示 BCVA ( p = .017)、SHRM 宽度/高度和流量信号 ( p < .05) 有显着改善。在没有 IRF/SRF 的眼睛中（n = 22；称为非渗出性 iCNV），有 7 只眼睛接受了治疗并显示出 SHRM 参数和 BCVA 的显着改善（p <.05）。4/15(26.67%) 未接受治疗的眼在 6 个月的随访中出现 IRF/SRF。